The latest market report published by Credence Research, Inc. “Global Laxatives Market By Drug Type (Senna, Bisacodyl, Docusate, Polyethylene Glycol 3350, Psyllium, Methylcellulose, Others) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026,” the laxatives market was valued at USD 4,739.42 Mn in 2015, and is expected to reach USD 6,948.07 Mn by 2022, expanding at a CAGR of 5.6% from 2016 to 2022.
Browse the full report at https://www.credenceresearch.com/report/laxatives-market
Browse the full report at https://www.credenceresearch.com/report/laxatives-market
Market Insights
Constipation is among the most common gastrointestinal malfunctions observed across all age groups. The prevalence of constipation in the general population is between 0.7% to 79% (with a median at 16%) (Epidemiology of constipation in children and adults: a systematic review, 2010), across all age groups. Constipation prevalence is high among the geriatric population and higher in females. The median province of constipation among children is 12%. With the growing burden of the condition there is a constant struggle among care givers and drug manufacturers to come up with more evolved treatment options.
Constipation is among the most common gastrointestinal malfunctions observed across all age groups. The prevalence of constipation in the general population is between 0.7% to 79% (with a median at 16%) (Epidemiology of constipation in children and adults: a systematic review, 2010), across all age groups. Constipation prevalence is high among the geriatric population and higher in females. The median province of constipation among children is 12%. With the growing burden of the condition there is a constant struggle among care givers and drug manufacturers to come up with more evolved treatment options.
The burden of constipation management in terms of time and cost is further higher in geriatric patients under palliative care. This patient group is more inclined towards prescription drug administration for treating constipation and thus forms a large consumer base for laxatives. Polyethylene Glycol is observed to be the largest segment in the global laxatives market and is expected to reach worth USD 1,271.98 by 2022. Moreover, it is also the fastest growing segment in the laxatives market.
Polyethylene glycol is an osmotic laxative and is used for short-term treatment of constipation and is used intermittently in cases of chronic constipation. Polyethylene glycol laxatives are also used intestinal purges for use colonoscopy preparation. Versatility of polyethylene glycol laxatives is observed to be a significant contributor to its rising demand in the laxatives market. Moreover, polyethylene glycol is also among the highest selling laxatives in the developed markets. MiraLAX by Schering-Plough (through licensing agreement with Braintree Laboratories) is the biggest brand name for polyethylene glycol laxatives and is claimed to be the most successful Rx to OTC switch in the laxatives category.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/57740
Table of Content
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Laxatives Market Portraiture
2.2. Global Laxatives Market, by Drug Type, 2017 (US$ Mn)
2.3. Global Laxatives Market, by Geography, 2017 (US$ Mn)
2.1. Global Laxatives Market Portraiture
2.2. Global Laxatives Market, by Drug Type, 2017 (US$ Mn)
2.3. Global Laxatives Market, by Geography, 2017 (US$ Mn)
Chapter 3. Laxatives Market Analysis
3.1. Laxatives Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Lifestyle Trends Increase the Risk of Constipation thus Consumption of Laxatives
3.2.1.2. Higher Prevalence of Constipation in Geriatric Population
3.2.2. Challenges
3.2.2.1. Demographic Reservations to Impact the Market
3.2.3. Opportunities
3.2.3.1. Emerging Markets Present Lucrative Opportunity for Growth
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017
3.1. Laxatives Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Lifestyle Trends Increase the Risk of Constipation thus Consumption of Laxatives
3.2.1.2. Higher Prevalence of Constipation in Geriatric Population
3.2.2. Challenges
3.2.2.1. Demographic Reservations to Impact the Market
3.2.3. Opportunities
3.2.3.1. Emerging Markets Present Lucrative Opportunity for Growth
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017
Do Inquiry before Buying for this report at https://www.credenceresearch.com/inquiry-before-buying/57740
Chapter 4. Global Laxatives Market, by Drug Type, 2016-2026 (US$ Mn)
4.1. Preface
4.1.1. Attractive Investment Proposition, by Drug Type, 2017
4.2. Senna
4.3. Bisacodyl
4.4. Docusate
4.5. Polyethylene Glycol 3350
4.6. Psyllium
4.7. Methylcellulose
4.8. Others
4.9. Phase Analysis (Market estimations by 2026)
4.9.1. Projected Sale of Phase III Drugs Estimated Till 2026 (US$ Mn)
4.9.1.1. BLI801
4.9.1.2. AJG555
4.9.1.3. Elobixibat
4.9.1.4. Tenapanor
4.9.2. Qualitative Information on Phase II and I drugs
4.1. Preface
4.1.1. Attractive Investment Proposition, by Drug Type, 2017
4.2. Senna
4.3. Bisacodyl
4.4. Docusate
4.5. Polyethylene Glycol 3350
4.6. Psyllium
4.7. Methylcellulose
4.8. Others
4.9. Phase Analysis (Market estimations by 2026)
4.9.1. Projected Sale of Phase III Drugs Estimated Till 2026 (US$ Mn)
4.9.1.1. BLI801
4.9.1.2. AJG555
4.9.1.3. Elobixibat
4.9.1.4. Tenapanor
4.9.2. Qualitative Information on Phase II and I drugs
Chapter 5. Global Laxatives Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.3. Europe Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.4. Asia Pacific Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.5. Latin America Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.6. Middle East & Africa (MEA) Laxatives Market Analysis, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. North America Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.3. Europe Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.4. Asia Pacific Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.5. Latin America Laxatives Market Analysis, 2016 – 2026 (US$ Mn)
5.6. Middle East & Africa (MEA) Laxatives Market Analysis, 2016 - 2026 (US$ Mn)
Chapter 6. Company Profiles
6.1. Bayer AG
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Application Portfolio
6.1.4. Key Developments
6.2. Boehringer Ingelheim Pharmaceuticals, Inc.
6.3. Braintree Laboratories, Inc.
6.4. GlaxoSmithKline Consumer Healthcare, L.P.
6.5. Procter & Gamble Company
6.6. Purdue Pharma L.P.
6.7. Sucampo Pharmaceuticals, Inc.
6.1. Bayer AG
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Application Portfolio
6.1.4. Key Developments
6.2. Boehringer Ingelheim Pharmaceuticals, Inc.
6.3. Braintree Laboratories, Inc.
6.4. GlaxoSmithKline Consumer Healthcare, L.P.
6.5. Procter & Gamble Company
6.6. Purdue Pharma L.P.
6.7. Sucampo Pharmaceuticals, Inc.
No comments:
Post a Comment